Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Sterol analysis identified four Candida albicans erg3 mutants in which ergosta 7,22-dienol, indicative of perturbations in sterol Δ 5,6 -desaturase (Erg3p) activity, comprised >5% of the total sterol fraction. The erg3 mutants (CA12, CA488, CA490, and CA1008) were all resistant to fluconazole, voriconazole, itraconazole, ketoconazole, and clotrimazole under standard CLSI assay conditions (MIC values, ≥256, 16, 16, 8, and 1 μg ml −1 , respectively). Importantly, CA12 and CA1008 retained an azole-resistant phenotype even when assayed in the presence of FK506, a multidrug efflux inhibitor. Conversely, CA488, CA490, and three comparator isolates (CA6, CA14, and CA177, in which ergosterol comprised >80% of the total sterol fraction and ergosta 7,22-dienol was undetectable) all displayed azole-sensitive phenotypes under efflux-inhibited assay conditions. Owing to their ergosterol content, CA6, CA14, and CA177 were highly sensitive to amphotericin B (MIC values, <0.25 μg ml −1 ); CA1008, in which ergosterol comprised <2% of the total sterol fraction, was less sensitive (MIC, 1 μg ml −1 ). CA1008 harbored multiple amino acid substitutions in Erg3p but only a single conserved polymorphism (E266D) in sterol 14α-demethylase (Erg11p). CA12 harbored one substitution (W332R) in Erg3p and no residue changes in Erg11p. CA488 and CA490 were found to harbor multiple residue changes in both Erg3p and Erg11p. The results suggest that missense mutations in ERG3 might arise in C. albicans more frequently than currently supposed and that the clinical significance of erg3 mutants, including those in which additional mechanisms also contribute to resistance, should not be discounted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Erg11, a cytochrome P450 enzyme, catalyzes the 14-methylation of lanosterol in C. albicans through three cycles13,14, each requiring two electrons from nicotinamide adenine dinucleotide phosphate (NADPH)-dependent Ncp1 reductase15,16.”
From Impairing the interaction between Erg11 and cytochrome P450 reductase Ncp1 enhances azoles’ antifungal activities (2025) · cites this paper as [13]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lower abundance of the enzyme has been observed in polyene-resistant species, which has been attributed to mutations in ERG2 [61,112], ERG3 [51], ERG5 [60], ERG6 [113], and ERG11 [60] genes, which encode enzymes involved in ergosterol synthesis.”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“several mutant ERG3 clinical isolates have been identified and reportedly possess resistance to the azole antifungals and cross-resistance to the polyene amphotericin B.”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [142]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acquired resistance is also rare, and involves reduced ergosterol biosynthesis and the production of alternative sterols to which amphotericin B has low affinity.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the latest cross-resistance between amphotericin B and azoles or caspofungin in Candida species are increasingly worrying [103,194,195,196,197].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [195]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 3×
“Following extensive use, resistance to antifungal azoles first emerged in HIV-positive patients (29, 31); resistant isolates are now isolated from other clinical settings, including chemotherapy and organ transplantation.”
Saville, S. P., Lazzell, A. L., Monteagudo, C., & Lopez-Ribot, J. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1053-1060.2003 · Cited by 655 · cited 1×
“Ergosterol maintains the integrity and fluidity of cell membranes (1) and consequently is understood to affect the morphology (20), virulence (30), and resistance characteristics of fungal pathogens.”
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · cited 1×
“albicans (6, 26, 28, 36, 38), and the importance of drug efflux transporters (10, 29, 31) and alterations in the protein target Erg11p (CYP51) (12, 15, 17, 27, 37) are among the most intensively studied.”
Sanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Resistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461 · cited 1×
“albicans (6, 26, 28, 36, 38), and the importance of drug efflux transporters (10, 29, 31) and alterations in the protein target Erg11p (CYP51) (12, 15, 17, 27, 37) are among the most intensively studied.”
Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398 · cited 6×
“b 14 -methylergosta-8,24(28)-dien-3 ,6 -diol.”
InfluentialMarichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351
Self-citationFranz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339 · cited 1×
“albicans (6, 26, 28, 36, 38), and the importance of drug efflux transporters (10, 29, 31) and alterations in the protein target Erg11p (CYP51) (12, 15, 17, 27, 37) are among the most intensively studied.”
Self-citation
Research works printed but not linked: 2
- 10. Kelly, S., D. C. Lamb, and D. E. Kelly. 1999. Antifungal efflux; a major mechanism of resistance in fungi. J. Antimicrob. Chemother. 44: 36-37.
- 32. Wang, W., D. Wang, R. Y. Li, et al. 1999. A study of the resistant mechanisms of Candida albicans to azole antifungal agents. Chin. J. Derm. Venereol. 13: 3-5.
Cited by
Items 101–172 of 172
Navarro-Mendoza, M. I., Arques, C. P., Parker, J. E., Xu, Z., Kelly, S. L., & Heitman, J. (2024) · mBio · doi:10.1128/mbio.01661-24 · Cited by 24
“Taken together, our results indicate that modifying the ergosterol biosynthetic pathway, and consequently, the content of ergosterol and intermediate sterols, may contribute to the observed drug susceptibility changes that we aim to address further.”
Self-citationWu, Y., Li, C., Wang, Z., Gao, J., Tang, Z., Chen, H., & Ying, C. (2018) · Medical Mycology · doi:10.1093/mmy/myx099 · Cited by 19
De-repression of CSP-1 activates adaptive responses to antifungal azoles.
Chen, X., Xue, W., Zhou, J., Zhang, Z., Wei, S., Liu, X., Sun, X., Wang, W., & Li, S. (2016) · Scientific Reports · doi:10.1038/srep19447 · Cited by 20
“Under KTC stress, eburicol (a substrate of ERG11) and 14 α -methyl-3,6-diol (a toxic14 α -methylated sterol), two intermediates in the ergosterol biosynthesis pathway, accumulated 21,22 .”
Zhang, M., Dong, P., Eldesouky, H. E., Zhan, Y., Lin, H., Wang, Z., Salama, E. A., Jusuf, S., Zong, C., Chen, Z., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c00900 · Cited by 21
Zhou, X., Hilk, A. L., Solis, N. V., de Sá, N. P., Hogan, B. M., Bierbaum, T. A., Poeta, M. D., Filler, S. G., Burrack, L. S., & Selmecki, A. M. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012389 · Cited by 20
Lim, H. J., Choi, M. J., Byun, S. A., Won, E. J., Park, J.-H., Choi, Y. J., Choi, H., Choi, H.-W., Kee, S., Kim, S. H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050515 · Cited by 19
Triclosan Antagonizes Fluconazole Activity against Candida albicans
Higgins, J., Pinjon, E., Oltean, H. N., White, T. C., Kelly, S. L., Martel, C. M., Sullivan, D. J., Coleman, D. C., & Moran, G. P. (2011) · Journal of Dental Research · doi:10.1177/0022034511425046 · Cited by 23
Self-citationLanna, M., Lovatto, J. E., de Almeida, J. N., Medeiros, E. A., Colombo, A. L., & García‐Effrón, G. (2025) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2025.101546 · Cited by 16
Molecular Mechanisms of Resistance to Antifungals in Candida albicans
Ruiz‐Baca, E., Arredondo-Sánchez, R. I., Corral-Pérez, K., López-Rodríguez, A., Meneses‐Morales, I., Ayala‐García, V. M., & Martínez-Rocha, A. L. (2021) · Infectious diseases · doi:10.5772/intechopen.96346 · Cited by 23
“albicans is also associated with an aminoacidic substitution in ERG11 and with ERG5 (sterol desaturase C-22) disfunction, again associated with an alternative membrane sterol composition [14, 39, 40].”
Luna-Tapia, A., Butts, A., & Palmer, G. E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01337-18 · Cited by 14
Hassoun, Y., Aptekmann, A. A., Keniya, M. V., Gomez, R. Y., Alayo, N., Novi, G., Quinteros, C., Kaya, F., Zimmerman, M. D., Cáceres, D. H., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012521 · Cited by 16
Li, W., Whiteway, M., Hang, S., Yu, J., Lu, H., & Jiang, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-62131-z · Cited by 13
Luna-Tapia, A., Parker, J. E., Kelly, S. L., & Palmer, G. E. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01044-21 · Cited by 14
Self-citationMechanisms of Drug Resistance in Fungi and Their Significance in Biofilms
Prasad, R., Shah, A. H., & Dhamgaye, S. (2014) · Springer series on biofilms · doi:10.1007/978-3-642-53833-9_4 · Cited by 14
Lv, Q., Qin, Y., Yan, L., Wang, L., Zhang, C., & Jiang, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00218 · Cited by 13
New Insights Regarding Yeast Survival following Exposure to Liposomal Amphotericin B
Teixeira‐Santos, R., Ricardo, E., Guerreiro, S. G., Costa‐de‐Oliveira, S., Rodrigues, A. G., & Pina‐Vaz, C. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00575-15 · Cited by 13
Benedetti, V. P., Savi, D. C., Aluízio, R., Adamóski, D., Kava, V. M., Galli-Terasawa, L. V., & Glienke, C. (2019) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0473-2018 · Cited by 14
Association of T916C (Y257H) mutation inCandida albicans ERG11with fluconazole resistance
Zhao, J., Xu, Y., & Li, C. (2012) · Mycoses · doi:10.1111/myc.12027 · Cited by 14
Hull, C. M., Purdy, N. J., & Moody, S. C. (2014) · Future Microbiology · doi:10.2217/fmb.13.160 · Cited by 11
What ‘Omics can tell us about antifungal adaptation
Ribeiro, G. F., Denes, E., Heaney, H., & Childers, D. S. (2021) · FEMS Yeast Research · doi:10.1093/femsyr/foab070 · Cited by 11
“…C. glabrata and S. cerevisiae, mutations in ERG genes confer some protection against AmB by depleting ergosterol from the plasma membrane (Geber et al. 1995; Kelly et al. 1996; Sanglard et al. 2003; Vandeputte et al. 2008; Martel et al. 2010; Hull et al. 2012b; Kodedová and Sychrová 2015).”
Deciphering the multidrug resistance paradigm in Candida auris
Santana, D. J., Cauldron, N. C., Rogers, P. D., & Cuomo, C. A. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01062-24 · Cited by 10
“Acquired amphotericin B resistance in other Candida species often involves mutations in ergosterol biosynthesis genes ERG2 (161, 162) and ERG6 or combined mutations in ERG11 with ERG3 or ERG5 (163, 164).”
Lavergne, R., Albassier, M., Hardouin, J.-B., Álvarez, C., Pagniez, F., Morio, F., Pape, P. L., & Ourliac‐Garnier, I. (2022) · Microorganisms · doi:10.3390/microorganisms10010104 · Cited by 10
Efficacy of Flavonoids in Combating Fluconazole Resistant Oral Candidiasis
Srivastava, D., Yadav, A., Naqvi, S., Awasthi, H., & Fatima, Z. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220324140257 · Cited by 11
Hsp90-Mediated Multi-Drug Resistance in DNA Polymerase-Defective Strains of Candida albicans
Utkalaja, B. G., Sahu, S. R., Parida, S. S., & Acharya, N. (2024) · Journal of Fungi · doi:10.3390/jof10030222 · Cited by 9
Córdova-Dávalos, L. E., Escobedo-Chávez, K., & Evangelista-Martínez, Z. (2017) · Archives of Biological Sciences · doi:10.2298/abs170908057c · Cited by 9
Zambom, C. R., da Fonseca, F. H., & Garrido, S. S. (2020) · Microorganisms · doi:10.3390/microorganisms8071024 · Cited by 9
Štefánek, M., Garaiová, M., Valček, A., Jordao, L., & Bujdáková, H. (2023) · Cells · doi:10.3390/cells12121579 · Cited by 7
Mechanisms of Drug Resistance in Candida albicans
Sanglard, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_15 · Cited by 11
Domán, M., Első, D., Pintér, K., Wehmann, E., Fehér, E., & Magyar, T. (2025) · Antibiotics · doi:10.3390/antibiotics14090902 · Cited by 6
“The genome plasticity noticed in our study through other genes involved in ergosterol biosynthesis indicates that alterations in enzyme cascade could occur; therefore, alternative pathways could develop as seen in Candida species [31,32].”
Ibe, C., Otu, A. A., & Pohl, C. H. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2448844 · Cited by 7
“Studies have shown that inactivation of ERG3 or GoF mutation is directly linked to fluconazole resistance in C. albicans [28,29].”
Heidary, F., Shams‐Ghahfarokhi, M., & Razzaghi‐Abyaneh, M. (2022) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2022.100535 · Cited by 6
Regan, J., DeJarnette, C. A., Luna-Tapia, A., Parker, J. E., Reitler, P., Barnett, S., Tucker, K. M., Kelly, S. L., & Palmer, G. E. (2022) · mBio · doi:10.1128/mbio.00115-22 · Cited by 5
Self-citationMolecular Mechanisms of Azole Resistance in Four Clinical Candida albicans Isolates
Shi, H., Zhang, Y., Zhang, M., Chang, W., & Lou, H. (2021) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0413 · Cited by 5
Mathematical Modeling of Fluconazole Resistance in the Ergosterol Pathway of Candida albicans
Yu, P. K., Espiritu, L. M., & Lao, A. R. (2022) · mSystems · doi:10.1128/msystems.00691-22 · Cited by 5
Recalcitrant cutaneous fungal infections—A growing problem
Koh, X. Q., & Pan, J. Y. (2023) · Australasian Journal of Dermatology · doi:10.1111/ajd.14115 · Cited by 6
Design and Synthesis of Ketoconazole Derivatives as Innovative Anti‐Infective Agents
Renzi, G., Angeli, A., Selleri, S., Spadini, C., Mezzasalma, N., Hull, M. T., Kelly, S. L., Capasso, C., Cabassi, C. S., Carta, F., et al. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70062 · Cited by 5
“…), and therefore, we performed our experiments on Candida albicans instead by administering 9a – d , 35a , 38 , 49b , 49c , and the reference drug KTZ at the final concentrations listed in Table 3, in agreement with experimentally determined KTZ MIC values [21] and MICs for M. globosa .”
Self-citationFeng, Y., Zhen, C., Li, W., Whiteway, M. S., Fang, X., Shen, X., Jiang, Y., & Lu, H. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128595 · Cited by 4
Omran, N.-Z. C., & Himratul-Aznita, W. H. (2016) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2016.1230479 · Cited by 4
Host-Fungal Interactions: Pathogenicity versus Immunity
Tavanti, A., Naglik, J. R., & Osherov, N. (2012) · International Journal of Microbiology · doi:10.1155/2012/562480 · Cited by 5
Deletion of RAP1 affects iron homeostasis, azole resistance, and virulence in Candida albicans
Yang, M.-C., Huang, W.-L., Chen, H., Lin, S.-H., Chang, Y.-S., Tseng, K., Lo, H., Wang, I., Lin, C.-J., & Lan, C. (2025) · mSphere · doi:10.1128/msphere.00155-25 · Cited by 3
Synthesis and Biological Evaluation of Itraconazole Derivatives: Design in an Old Scaffold
Zhong, S., Kalamatianou, A., Scalese, G., O’Beirne, C., Redrado, M., Blacque, O., Picot, C., Tomasoni, C., Logé, C., Albassier, M., et al. (2025) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5c02730 · Cited by 2
Kubica, S., Szulińska, W., Kruszniewska‐Rajs, C., Kimsa‐Dudek, M., Olender, A., Bogut, A., Szukała, M., Dąbrowski, W., Pietrzak, D., Gagoś, M., et al. (2025) · Folia Microbiologica · doi:10.1007/s12223-025-01298-w · Cited by 2
Lipidomics Approaches: Applied to the Study of Pathogenesis in Candida Species
Singh, A., Khandelwal, N., & Prasad, R. (2019) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-13035-0_8 · Cited by 2
Nonantifungal Clinical Drug Interventions and Human-Commensal Fungi: What are we Selecting?
Hull, C. M., & Purdy, N. J. (2013) · Future Microbiology · doi:10.2217/fmb.13.45 · Cited by 2
Advances in Genomics of Human Fungal Pathogens
Kollath, D. R., Teixeira, M. D. M., & Barker, B. M. (2018) · Population genomics · doi:10.1007/13836_2018_41 · Cited by 5
Unnikrishnan, V. K., Sundaramoorthy, N. S., Manivannan, R., Shanthi, M., Gnanadhas, D. P., Alexandar, S. P., Ulaganathan, V., Ramesh, S., & Nagarajan, S. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130529 · Cited by 1
Gim3 buffers and potentiates de novo mutations that affect fluconazole susceptibility in yeast
Tawfeeq, M. T., Konstantinidis, D., Iraizos, A. L. R., Genechten, W. V., Vreys, J., Vermeersch, L., Voordeckers, K., Dijck, P. V., & Verstrepen, K. J. (2026) · EMBO Reports · doi:10.1038/s44319-026-00702-x · Cited by 1
Use of Novel Tools to Probe Drug Resistance in Fungi
Zhao, Y., & Perlin, D. S. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_21 · Cited by 1
Candidiasis and the impact of flow cytometry on antifungal drug discovery
Ku, T. S. N., Bernardo, S. M., Walraven, C. J., & Lee, S. A. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1377179 · Cited by 1
Idnurm, A., & Xu, M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06917-6 · Cited by 1
Drug resistance in pathogenic species of Candida
Jaiswal, N., & Kumar, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91643-1.00014-4 · Cited by 3
Doorley, L. A. (2023) · doi:10.21007/etd.cghs.2023.0620 · Cited by 1
Blosser, S. J. (2013) · Montana State University ScholarWorks (Montana State University)
Regulation of Fungal Drug Resistance and Morphogenesis by Lysine Deacetylases
Li, X. (2015) · TSpace (University of Toronto)
Amphotericin B fungicidal activity: a comprehensive analysis of fungal recovery
Teixeira‐Santos, R. (2017) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/jdq4-9p24 · Cited by 1
The Research Progress on Occurrence of Candida Drug Resistance
付, 婉. (2017) · Advances in Microbiology · doi:10.12677/amb.2017.64013
Use of Novel Tools to Probe Drug Resistance in Fungi
Zhao, Y., & Perlin, D. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_21-1
Fungal diseases and antifungal drugs
Kumar, A., & Jha, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18744-5.00002-2
Digvijaya, Mittal, S., Mittal, P., Singh, R., Gupta, S., Singh, T., Khan, R., Alzobaidi, N., & Alhalmi, A. (2024) · Scientifica · doi:10.1155/2024/9978076
Bohner, F. (2024) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.12031
Thite, T., Jain, P., Iyer, K. A., Tenchov, R., Sasso, J. M., Balande, U., Maind, A., & Zhou, Q. A. (2025) · ChemRxiv · doi:10.26434/chemrxiv-2025-86lcw
Antimykotische Zielstrukturen in Aspergillus fumigatus
Geißel, B. (2024) · doi:10.5282/edoc.33959
Rare yeast and resistance mechanisms
Hansen, A. P. (2019) · Digital Library of the University of Innsbruck (University of Innsbruck)
Zhang, D., XiaoXing, L., Zhao, X., Yan, Z., Wang, W., & Dai, G. (2026) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2026.2655675 · Cited by 2
Diploidy alters the path of fluconazole adaptation in Candida glabrataPreprint
Galeota-Sprung, B., Fernandez, A., Wright, C., Tejada, R. S., & Sniegowski, P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.727327
Micafungin exposure drives multidrug resistance in Clavispora lusitaniaePreprint
Wash, E., Scott, N. E., Metzner, K., Zhou, X., Dasilva, D., de Sá, N. P., Usmani, S. A., Sa, N. F. V. D., Poeta, M. D., & Selmecki, A. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.29.735437
“Therefore, we posit that resistance to azoles and polyenes is consistent with previously reported models of ERG3 loss of function: 14α-methylergosta-8,24(28)-dien-3,6-diol is not synthesized, conferring azole resistance, and ergosterol is not synthesized, conferring polyene resistance (15, 97).”
InfluentialLineage-specific adaptation and resistance in Candida albicans
Fernandes, M. Z., Maldonado, E., Martinez‐de‐Oliveira, J., Rolo, J., & Palmeira-de-Oliveira, A. (2026) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2026.104116
Zheng, Y., Xike, T., Xiaofeng, P., Yinmei, F., Lida, M., Xiaolu, L., & Xiao, M. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s629534
“21,22 For example, the R135I substitution in Candida parapsilosis Erg3p and W332R/H243N mutations in C. albicans Erg3p reduced triazole susceptibility by disrupting ergosterol synthesis, leading to the accumulation of aberrant sterol intermediates and perturbed the sterol composition of fungal…”
Ye, S., Cui, Z., Zhou, M., Hu, C., Yu, P., Zhang, L., Li, S., & Sun, X. (2026) · mBio · doi:10.1128/mbio.02021-26
“Previous studies have demonstrated that accumulation of 14α-methyl-3,6-diol can alter membrane biophysical properties by reducing rigidity and phase heterogeneity, thereby conferring fluconazole hyper-resistance in Saccharomyces cerevisiae and azole resistance in Candida albicans (48, 49).”
Metadata
- Authors
- Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L.
- Affiliations
- Swansea University (GB)
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Kelly, Steven L.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-11
- Volume
- 54
- Issue
- 11
- Pages
- 4527-4533
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2976150
- OpenAlex
- W2109056652
- Cited by
- 168
- References
- 39
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 11 · 2023: 12 · 2022: 9 · 2021: 13 · 2020: 12 · 2019: 13 · 2018: 11 · 2017: 21 · 2016: 8 · 2015: 4 · 2014: 13 · 2013: 10 · 2012: 9
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Funders
- Engineering and Physical Sciences Research Council
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, azole resistance, sterol 14α-demethylase, ergosterol, fluconazole resistance, voriconazole resistance, ketoconazole resistance, clotrimazole resistance, amphotericin B susceptibility, FK506, efflux pump inhibition, missense mutations, antifungal resistance
- MeSH terms
- Amphotericin B, Antifungal Agents, Azoles, Candida albicans, Clotrimazole, Ergosterol, Ketoconazole, Microbial Sensitivity Tests, Mutation, Oxidoreductases, Pyrimidines, Triazoles, Fluconazole, Itraconazole, Drug Resistance, Fungal, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.